The MS Pill That Beat Standard Therapy and Cleared the Safety Bar Its Rival Could Not
A Novartis oral pill for relapsing multiple sclerosis outperformed standard therapy in two large Phase III trials, and unlike a rival BTK inhibitor the FDA declined over liver concerns, it showed no
Follow